Chongqing Zhifei Biological Products Future Growth
Future criteria checks 3/6
Chongqing Zhifei Biological Products is forecast to grow earnings and revenue by 22.8% and 9.3% per annum respectively. EPS is expected to grow by 20.6% per annum. Return on equity is forecast to be 24.6% in 3 years.
Key information
22.8%
Earnings growth rate
20.6%
EPS growth rate
Biotechs earnings growth | 34.3% |
Revenue growth rate | 9.3% |
Future return on equity | 24.6% |
Analyst coverage | Good |
Last updated | 29 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 63,360 | 12,095 | 12,079 | 11,945 | 4 |
12/31/2025 | 66,731 | 12,785 | 7,784 | 9,347 | 13 |
12/31/2024 | 57,093 | 9,200 | 1,986 | 2,760 | 8 |
3/31/2024 | 53,141 | 7,496 | 4,665 | 5,763 | N/A |
12/31/2023 | 52,918 | 8,070 | 7,862 | 8,996 | N/A |
9/30/2023 | 49,712 | 8,462 | 2,476 | 3,586 | N/A |
3/31/2023 | 40,596 | 7,648 | 2,951 | 4,266 | N/A |
1/1/2023 | 38,264 | 7,539 | 536 | 1,989 | N/A |
9/30/2022 | 36,647 | 7,412 | -360 | 1,175 | N/A |
6/30/2022 | 35,835 | 8,447 | -1,151 | 596 | N/A |
3/31/2022 | 35,567 | 11,193 | 3,452 | 5,305 | N/A |
12/31/2021 | 30,652 | 10,209 | 6,575 | 8,508 | N/A |
9/30/2021 | 25,969 | 9,226 | 7,515 | 9,350 | N/A |
6/30/2021 | 21,368 | 7,287 | 8,050 | 9,627 | N/A |
3/31/2021 | 16,482 | 3,723 | 2,691 | 3,868 | N/A |
12/31/2020 | 15,190 | 3,301 | 2,670 | 3,497 | N/A |
9/30/2020 | 13,971 | 3,082 | 2,554 | 3,272 | N/A |
6/30/2020 | 12,542 | 2,724 | 1,038 | 1,604 | N/A |
3/31/2020 | 10,928 | 2,381 | 691 | 1,318 | N/A |
12/31/2019 | 10,587 | 2,366 | 794 | 1,367 | N/A |
9/30/2019 | 9,400 | 2,128 | 598 | 1,145 | N/A |
6/30/2019 | 8,195 | 1,916 | 247 | 764 | N/A |
3/31/2019 | 6,684 | 1,694 | -422 | 82 | N/A |
12/31/2018 | 5,228 | 1,451 | 106 | 586 | N/A |
9/30/2018 | 4,068 | 1,234 | -326 | 98 | N/A |
6/30/2018 | 2,969 | 943 | -172 | 170 | N/A |
3/31/2018 | 2,019 | 632 | 47 | 298 | N/A |
12/31/2017 | 1,343 | 432 | N/A | 204 | N/A |
9/30/2017 | 942 | 311 | N/A | 207 | N/A |
6/30/2017 | 707 | 192 | N/A | 126 | N/A |
3/31/2017 | 464 | 34 | N/A | 87 | N/A |
12/31/2016 | 446 | 33 | N/A | 90 | N/A |
9/30/2016 | 431 | 44 | N/A | 253 | N/A |
6/30/2016 | 512 | 101 | N/A | 207 | N/A |
3/31/2016 | 660 | 209 | N/A | 265 | N/A |
12/31/2015 | 713 | 197 | N/A | 223 | N/A |
9/30/2015 | 779 | 172 | N/A | 143 | N/A |
6/30/2015 | 805 | 160 | N/A | 165 | N/A |
3/31/2015 | 835 | 153 | N/A | 167 | N/A |
12/31/2014 | 801 | 148 | N/A | 161 | N/A |
9/30/2014 | 777 | 136 | N/A | 153 | N/A |
6/30/2014 | 735 | 124 | N/A | 179 | N/A |
3/31/2014 | 758 | 132 | N/A | 157 | N/A |
12/31/2013 | 780 | 130 | N/A | 222 | N/A |
9/30/2013 | 844 | 203 | N/A | 76 | N/A |
6/30/2013 | 858 | 209 | N/A | 125 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300122's forecast earnings growth (22.8% per year) is above the savings rate (2.9%).
Earnings vs Market: 300122's earnings (22.8% per year) are forecast to grow slower than the CN market (24.3% per year).
High Growth Earnings: 300122's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 300122's revenue (9.3% per year) is forecast to grow slower than the CN market (14.6% per year).
High Growth Revenue: 300122's revenue (9.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300122's Return on Equity is forecast to be high in 3 years time (24.6%)